DCF Tool

ENDP

Endo International plc – Pharmaceutical Preparation Manufacturing
Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them.
Analysis Results
Intrinsic Value $128.02
Latest Price $0.44
Relative Value 100% undervalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Billions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 5.7%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 6.9%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 5.7%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (billion) Present value (billion)
2022 1.37 1.28
2023 1.45 1.27
2024 1.53 1.25
2025 1.61 1.24
2026 1.71 1.22
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 35.6 billion. This corresponds to a present value of 23.8 billion.

Intrinsic Value Per Share

The total present value of the projected cash flows is 6.26 billion. Adding in the terminal value gives a total present value of 30.1 billion.

There are presently 235.0 million outstanding shares, so the intrinsic value per share is 128.02.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 2,714,586,000
Current Cash 1,507,196,000
Current Liabilities 1,629,962,000
Current Debt 200,342,000
Non-Cash Working Capital (NCWC) -222,230,000
Change in NCWC -202,377,000
EBIT 761,822,000
Tax Provision 22,478,000
Depreciation and Amortization 457,098,000
Capital Expenditure -77,929,000
Unlevered Free Cash Flow 938,614,000
Current Assets 2,413,258,000
Current Cash 1,213,437,000
Current Liabilities 1,253,824,000
Current Debt 34,150,000
Non-Cash Working Capital (NCWC) -19,853,000
Change in NCWC 274,599,000
EBIT 605,315,000
Tax Provision -273,982,000
Depreciation and Amortization 518,807,000
Capital Expenditure -69,971,000
Unlevered Free Cash Flow 1,328,750,000
Current Assets 2,586,218,000
Current Cash 1,454,531,000
Current Liabilities 1,460,289,000
Current Debt 34,150,000
Non-Cash Working Capital (NCWC) -294,452,000
Change in NCWC 427,457,000
EBIT 579,528,000
Tax Provision 15,680,000
Depreciation and Amortization 612,862,000
Capital Expenditure -63,854,000
Unlevered Free Cash Flow 1,555,993,000
Current Assets 2,343,150,000
Current Cash 1,149,113,000
Current Liabilities 1,950,096,000
Current Debt 34,150,000
Non-Cash Working Capital (NCWC) -721,909,000
Change in NCWC 180,323,000
EBIT 480,089,000
Tax Provision 22,935,000
Depreciation and Amortization 723,707,000
Capital Expenditure -83,398,000
Unlevered Free Cash Flow 1,300,721,000
Current Assets 2,271,077,000
Current Cash 986,605,000
Current Liabilities 2,220,909,000
Current Debt 34,205,000
Non-Cash Working Capital (NCWC) -902,232,000
Change in NCWC -470,821,000
EBIT 437,489,000
Tax Provision -250,293,000
Depreciation and Amortization 983,765,000
Capital Expenditure -125,654,000
Unlevered Free Cash Flow 824,779,000
Current Assets 2,589,459,000
Current Cash 517,250,000
Current Liabilities 2,634,745,000
Current Debt 131,125,000
Non-Cash Working Capital (NCWC) -431,411,000
Change in NCWC -492,674,000
EBIT 422,391,000
Tax Provision -700,084,000
Depreciation and Amortization 983,309,000
Capital Expenditure -138,856,000
Unlevered Free Cash Flow 774,170,000
Current Assets 3,475,152,000
Current Cash 272,382,000
Current Liabilities 3,474,312,000
Current Debt 332,805,000
Non-Cash Working Capital (NCWC) 61,263,000
Change in NCWC 102,767,000
EBIT 346,349,000
Tax Provision -1,137,465,000
Depreciation and Amortization 632,756,000
Capital Expenditure -81,774,000
Unlevered Free Cash Flow 1,000,098,000
Current Assets 3,307,472,000
Current Cash 409,568,000
Current Liabilities 3,099,245,000
Current Debt 159,837,000
Non-Cash Working Capital (NCWC) -41,504,000
Change in NCWC -1,091,371,000
EBIT 534,900,000
Tax Provision -401,840,000
Depreciation and Amortization 331,651,000
Capital Expenditure -80,425,000
Unlevered Free Cash Flow -305,245,000
Current Assets 2,854,507,000
Current Cash 526,597,000
Current Liabilities 1,696,672,000
Current Debt 418,629,000
Non-Cash Working Capital (NCWC) 1,049,867,000
Change in NCWC 1,217,471,000
EBIT 585,580,000
Tax Provision -24,067,000
Depreciation and Amortization 255,663,000
Capital Expenditure -96,483,000
Unlevered Free Cash Flow 1,962,231,000
Current Assets 1,969,234,000
Current Cash 547,916,000
Current Liabilities 1,728,020,000
Current Debt 139,098,000
Non-Cash Working Capital (NCWC) -167,604,000
Change in NCWC -374,567,000
EBIT 641,303,000
Tax Provision -53,562,000
Depreciation and Amortization 285,524,000
Capital Expenditure -99,818,000
Unlevered Free Cash Flow 452,442,000

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.